Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgk...
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
About this item
Full title
Author / Creator
Hutchings, Martin , Mous, Rogier , Clausen, Michael Roost , Johnson, Peter , Linton, Kim M , Chamuleau, Martine E D , Lewis, David John , Sureda Balari, Anna , Cunningham, David , Oliveri, Roberto S , Elliott, Brian , DeMarco, Dena , Azaryan, Ada , Chiu, Christopher , Li, Tommy , Chen, Kuo-mei , Ahmadi, Tahamtan and Lugtenburg, Pieternella J
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T-cell-mediated cytotoxic activity against CD20+ malignant B cells.
For the dose-escalation part of this phase...
Alternative Titles
Full title
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Authors, Artists and Contributors
Author / Creator
Mous, Rogier
Clausen, Michael Roost
Johnson, Peter
Linton, Kim M
Chamuleau, Martine E D
Lewis, David John
Sureda Balari, Anna
Cunningham, David
Oliveri, Roberto S
Elliott, Brian
DeMarco, Dena
Azaryan, Ada
Chiu, Christopher
Li, Tommy
Chen, Kuo-mei
Ahmadi, Tahamtan
Lugtenburg, Pieternella J
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2571927385
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2571927385
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(21)00889-8
